Zynerba Pharmaceuticals Inc. (ZYNE) is a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments.The company has two synthetic cannabinoid therapeutics under development namely, ZYN002 and ZYN001.ZYN002 is a synthetic Cannabidiol (CBD), formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.A phase II study of ZYN002 in refractory epilepsy, dubbed STAR, is underway. The results from this study are expected to be reported in the first half of 2017.Additional phase II trials of ZYN002 in osteoarthritis and Fragile X syndrome are expected to be initiated in the second half of 2016.The other drug candidate of Zynerba is ZYN001, a pro-drug of THC, being explored for fibromyalgia and peripheral neuropathic pain.The company expects to initiate phase 1 studies to evaluate the PK profile and tolerability of ZYN001 in healthy volunteers in the second half of 2016.ZYNE has lost over 7% of its value year-to-date and trades around $8.90.